Premium
Effect of 5‐imino‐2,2,4,4‐tetrakis (trifluoromethyn imidazolidine (EXP 338) on spasticity: A quantitative evaluation
Author(s) -
Levine Irving M.,
Jossmann Paul B.,
Friend Dale G.,
DeAngelis Vincent
Publication year - 1968
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt196894448
Subject(s) - spasticity , hypertonia , spastic , muscle tone , imidazolidine , polygraph , medicine , anesthesia , physical medicine and rehabilitation , psychology , chemistry , social psychology , organic chemistry , cerebral palsy
In preclinical studies, 5‐imino‐2,2,4,4‐tetrakis (trifluoromethyl) imidazolidine (EXP 338) revealed potential muscle relaxant action at nontoxic levels in experimental animals. Our evaluation was carried out on 15 spastic multiple sclerosis patients. Eotablished methods of inducing spasticity and recording skeletal muscle hypertonia and quantitatively extracting integrated electromyogram data were used. Five patients were tested directly in the polygraph laboratory and 10 were tested at home via telephone telemetry (telemedography). Blood and urine were unaffected by the test drug. Adverse effects included muscle weakness, insomnia, paranoid reaction, sexual excitement, irritability, dry mouth, and limb pains. The alerting effect of EXP 338 suggests its trial as an antidepressant. The polygraph data revealed that a daily dose of 10 to 20 mg. of EXP 338 resulted in an average reduction of 62 per cent in skeletal muscle hypertonia in half the spastic subjects tested.